WEED Inc. Acquires Hempirical Genetics, With Over 250 Proprietary Cannabis & Hemp Strains For $750K
WEED Inc. Acquires Hempirical Genetics, With Over 250 Proprietary Cannabis & Hemp Strains For $750K
Miller stated, "I've known Glenn Martin for 50+ years and honored to take the helm of HEMP BioSciences to buildout our genetic studies. My goal is to bring the strongest, highest quality THC and hemp products to market at affordable prices. "Double the quality, half the price" should be the mantra for the cannabis industry, while creating diversity & equality to the cannabis sector. Our Veterans have been highly overlooked, and I look to develop vet programs at low or no cost, which I know is a priority of Glenn and mine."WEED, Inc. (OTCQB:BUDZ) a global cannabis & hemp bioresearch company based in the USA, focused on the development and application of cannabis-derived compounds for the treatment of human and animal diseases, acquired 100% of Hempirical Genetics, LLC, for 2 million shares of common stock valued at $.25 per share and $250,000 in cash over 4 years. One million shares and $10,000 was paid on signing this agreement.
雜草公司 （OTCQB：BUDZ）總部位於美國的全球大麻和大麻生物研究公司，專注於大麻衍生化合物的開發和應用，用於治療人類和動物疾病， 收購了 100％ 的麻狀遺傳學有限責任公司，為 2 百萬股 價值每股 0.25 美元的普通股 以及 25 萬美元的現金 超過 4 年。簽署本協議時支付了一百萬股和 10,000 美元。
Glenn E. Martin, WEED, Inc.'s CEO stated, "Our teams in USA, Australia and Israel are excited that a pipeline of Original "Landrace" strains from the 1970s' can now be moved into clinical trials and product development for the global market. WEED now has over 15 "PURE" original, pristine, F-1 grade cannabis strains today, including, Panama Red, Acapulco Gold, Red Bud Colombian & Santa Marta Gold. Our newly acquired inventory includes over 30 CBD & CBG strains as WEED believes that multiple combinations of precise cannabinoid strains will create the entourage effect to achieve the medical outcome desired. Eventually, WEED plans to bring our unique desired strains to the Adult Use markets once the "Law of the Land" brings back the Freedoms lost 70+ years ago."
格伦 ·E· 马丁, 雜草, 公司。's 首席執行官表示：「我們在美國，澳大利亞和以色列的團隊感到興奮的是，來自 20 世紀 70 年代的原始「Landrace」菌株現在可以轉移到全球市場的臨床試驗和產品開發中。雜草現在有超過 15」純「原始，原始的， F-1 今天級大麻菌株, 包括, 巴拿馬紅，阿卡普爾科金，紅芽哥倫比亞和聖瑪爾塔黃金。我們新獲得的庫存包括超過 30 CBD & CBG 菌株，因為 WEED 認為，精確的大麻素菌株的多種組合將創建隨從效應，以實現所需的醫療結果.最終，WEED 計劃一旦「土地法律」帶回了 70 多年前失去的自由，將我們獨特所需的菌株帶回成人使用市場。」
Jeffery Miller, the previous owner of Hempirical Genetics, will lead the charge in strain & product development as HEMP BioScience's new CEO. Martin continued, "I've known Jeff for a half a century. His horticulture skills and dedication the Cannabaceae plant cannot be duplicated. I'm extremely proud to have my old friend and his team, (whose strains WEED bought in the acquisition), which we believe will bring year-over-year success to the benefit of WEED's shareholders."
杰弗里·米勒, 以前的所有者麻狀遺傳學, 將導致電荷在應變 & 產品開發 大麻生物科學的新任首席執行官。馬丁繼續說：「我認識傑夫半個世紀了。他的園藝技能和奉獻精神的大麻科植物不能被複製.我非常自豪能有我的老朋友和他的團隊，（他們的 WEED 菌株在收購中購買），我們相信這將為 WEED 的股東帶來同比去年的成功。」
Miller stated, "I've known Glenn Martin for 50+ years and honored to take the helm of HEMP BioSciences to buildout our genetic studies. My goal is to bring the strongest, highest quality THC and hemp products to market at affordable prices. "Double the quality, half the price" should be the mantra for the cannabis industry, while creating diversity & equality to the cannabis sector. Our Veterans have been highly overlooked, and I look to develop vet programs at low or no cost, which I know is a priority of Glenn and mine."
米勒說,「我已經知道格倫·馬丁 50+ 多年，很榮幸能掌舵大麻生物科學建立我們的基因研究.我的目標是以實惠的價格將最強，最優質的 THC 和大麻產品推向市場。「質量翻倍，價格的一半」應該是大麻行業的口頭禪，同時創造了對大麻行業的多樣性和平等。我們的退伍軍人被高度忽視，我希望以低成本或免費開發獸醫計劃，我知道這是 Glenn 和我的首要任務。」
Photo by CRYSTALWEED cannabis on Unsplash
照片由水晶雜草大麻在未飛濺
譯文內容由第三人軟體翻譯。
